Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck | Zendy

Kim Sung | Zendy; Eleff Michael | Zendy; Nicolaou Nicos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck

Author(s) -

Kim Sung,

Eleff Michael,

Nicolaou Nicos

Publication year - 2011

Publication title -

head and neck

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.012

H-Index - 127

eISSN - 1097-0347

pISSN - 1043-3074

DOI - 10.1002/hed.21299

Subject(s) - cetuximab , medicine , head and neck squamous cell carcinoma , lymph , oncology , radiation therapy , head and neck cancer , basal cell , head and neck , primary tumor , surgery , cancer , metastasis , pathology , colorectal cancer

Background. Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy.Methods. We present the case of a 92‐year‐old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m 2 loading dose and a 250 mg/m 2 weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues.Results. The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response.Conclusions. Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile. © 2009 Wiley Periodicals, Inc. Head Neck, 2011

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research